YPEG-Somatropin is under clinical development by Xiamen Amoytop Biotech and currently in Phase II for Idiopathic Short Stature. According to GlobalData, Phase II drugs for Idiopathic Short Stature have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how YPEG-Somatropin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YPEG-somatropin is under development for the treatment of growth hormone deficiency (GHD), born small for gestational age, turner syndrome, idiopathic short stature. The therapeutic candidate is administered through subcutaneous route. It is a pegylated long-acting recombinant human growth hormone developed based on Y-shaped PEGylation modification technique which enables attachment of the linker to the therapeutic moiety with PEG through covalent bond. The therapeutic candidate targets somatropin receptor.
Xiamen Amoytop Biotech overview
Xiamen Amoytop Biotech is a biopharmaceutical company that manufactures, develops and markets recombinant pegylated protein drugs. The company’s product portfolio includes peginterferon Alfa-2b, Molgramostim, filgrastim, oprelvekin and reagents. Its human granulocyte stimulating factor injections comprise Terli and Terzine, which are used for the treatment of neutropenia and tumor radiotherapy
For a complete picture of YPEG-Somatropin’s drug-specific PTSR and LoA scores, buy the report here.